Boston Scientific’s shares fell 4.5% after a cyberattack disrupted global operations, including order processing, following its detection on Tuesday. The company did not provide a timeline for restoring normal operations.
The incident adds to a wave of cyber threats targeting the healthcare sector, following recent breaches at competitors Stryker, Abbott, Medtronic and Danish drugmaker Novo Nordisk. Boston Scientific did not specify the nature of the attack or the systems affected.
Analyst Vijay Kumar of Evercore noted that if operations remain disrupted for roughly three weeks—similar to the Stryker incident earlier this year—third-quarter revenue could decline by 600 to 700 basis points. The company has not yet quantified the financial impact of the outage.
